

EPS History		EPSmg History	
Next Fiscal Year Estimate	\$6.94	Next Fiscal Year Estimate	\$3.92
Dec2017	\$0.53	Dec2017	\$2.43
Dec2016	-\$0.08	Dec2016	\$3.04
Dec2015	\$10.83	Dec2015	\$3.90
Dec2014	\$0.56	Dec2014	\$0.36
Dec2013	\$0.55	Dec2013	\$0.20
Dec2012	-\$0.03	Dec2012	-\$0.41
Dec2011	\$0.49	Dec2011	\$0.33
Dec2010	-\$0.53	Dec2010	\$0.70
Dec2009	-\$0.10	Dec2009	\$1.25
Dec2008	-\$6.18	Dec2008	\$1.43
Dec2007	\$17.22	Dec2007	\$3.50
Dec2006	-\$2.34	Dec2006	-\$3.69
Dec2005	-\$2.94	Dec2005	-\$4.48
Dec2004	-\$3.66	Dec2004	-\$5.42
Dec2003	-\$8.16	Dec2003	-\$6.51
Dec2002	-\$4.56	Dec2002	-\$6.72
Dec2001	-\$4.32	Balance Sheet Information 6/1/2018	
Dec2000	-\$8.10	Total Current Assets	\$1,480,470,000
Dec1999	-\$9.48	Total Current Liabilities	\$632,850,000
Dec1998	-\$17.52	Long-Term Debt	\$595,912,000
		Total Assets	\$1,858,284,000
		Intangible Assets	\$328,399,000
		Total Liabilities	\$1,238,471,000
		Shares Outstanding (Diluted Average)	24,438,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor. The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company [Ligand Pharmaceuticals Inc Valuation – Initial Coverage \\$LGND](#)

Other ModernGraham posts about related companies

- [Supernus Pharmaceuticals Inc Valuation – August 2018 \\$SUPN](#)
- [Lannett Co Inc Valuation – August 2018 \\$LCI](#)
- [Spectrum Pharmaceuticals Inc Valuation – August 2018 \\$SPPI](#)
- [Akorn Inc Valuation – July 2018 \\$AKRX](#)
- [Mallinckrodt PLC Valuation – July 2018 \\$MNK](#)
- [Bristol-Myers Squibb Company Valuation – June 2018 \\$BMJ](#)
- [Biogen Inc Valuation – June 2018 \\$BIIB](#)
- [Mylan NV Valuation – June 2018 \\$MYL](#)
- [Amgen Inc Valuation – June 2018 \\$AMGN](#)
- [Celgene Corp Valuation – June 2018 \\$CELG](#)